MX388751B - Compuestos de imidazo-piperidina fusionada como inhibidores de jak. - Google Patents

Compuestos de imidazo-piperidina fusionada como inhibidores de jak.

Info

Publication number
MX388751B
MX388751B MX2019012942A MX2019012942A MX388751B MX 388751 B MX388751 B MX 388751B MX 2019012942 A MX2019012942 A MX 2019012942A MX 2019012942 A MX2019012942 A MX 2019012942A MX 388751 B MX388751 B MX 388751B
Authority
MX
Mexico
Prior art keywords
compound
piperidine compounds
jak inhibitors
fused imidazo
formula
Prior art date
Application number
MX2019012942A
Other languages
English (en)
Other versions
MX2019012942A (es
Inventor
Glenn D Crater
Hao Zhang
Jerry Nzerem
Lan Jiang
Marta Dabros
Melanie A Kleinschek
Noah Benjamin
Paul R Fatheree
Robert Murray Mckinnell
Venkat R Thalladi
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2019012942A publication Critical patent/MX2019012942A/es
Publication of MX388751B publication Critical patent/MX388751B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un compuesto de fórmula 1 (ver fórmula 1) o una sal farmacéuticamente aceptable del mismo, útil como inhibidor de JAK. La invención también provee formas cristalinas del compuesto, composiciones farmacéuticas que comprenden tal compuesto, métodos para usar el compuesto para tratar enfermedades susceptibles a un inhibidor de JAK, y procesos e intermediarios útiles para preparar el compuesto.
MX2019012942A 2017-05-01 2018-04-30 Compuestos de imidazo-piperidina fusionada como inhibidores de jak. MX388751B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492574P 2017-05-01 2017-05-01
PCT/US2018/030148 WO2018204238A1 (en) 2017-05-01 2018-04-30 Fused imidazo-piperidine jak inhibitor compound

Publications (2)

Publication Number Publication Date
MX2019012942A MX2019012942A (es) 2019-12-16
MX388751B true MX388751B (es) 2025-03-20

Family

ID=62165730

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012942A MX388751B (es) 2017-05-01 2018-04-30 Compuestos de imidazo-piperidina fusionada como inhibidores de jak.

Country Status (32)

Country Link
US (3) US10493077B2 (es)
EP (1) EP3601283B1 (es)
JP (1) JP7098656B2 (es)
KR (1) KR102550225B1 (es)
CN (1) CN110573508B (es)
AR (1) AR111495A1 (es)
AU (1) AU2018261593B2 (es)
BR (1) BR112019022648A2 (es)
CA (1) CA3056283A1 (es)
CL (1) CL2019003086A1 (es)
CO (1) CO2019011809A2 (es)
CY (1) CY1125051T1 (es)
DK (1) DK3601283T3 (es)
EA (1) EA201992601A1 (es)
ES (1) ES2908756T3 (es)
HR (1) HRP20220330T1 (es)
IL (1) IL270231B2 (es)
LT (1) LT3601283T (es)
MA (1) MA47970B1 (es)
MD (1) MD3601283T2 (es)
MX (1) MX388751B (es)
NZ (1) NZ757570A (es)
PH (1) PH12019502264A1 (es)
PL (1) PL3601283T3 (es)
PT (1) PT3601283T (es)
RS (1) RS62995B1 (es)
SG (1) SG11201908604YA (es)
SI (1) SI3601283T1 (es)
SM (1) SMT202200079T1 (es)
TW (1) TWI760486B (es)
UA (1) UA124478C2 (es)
WO (1) WO2018204238A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016350816B2 (en) 2015-11-03 2020-06-25 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
EA037261B1 (ru) 2017-03-09 2021-03-01 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Ингибиторы jak, содержащие 4-членный гетероциклический амид
CA3059785A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CA3108848A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
ES2955717T3 (es) 2018-09-04 2023-12-05 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK
SI3837258T1 (sl) 2018-09-04 2024-09-30 Theravance Biopharma R&D Ip, Llc Dimetil amino azetidin amidi, ki se uporabljajo kot JAK zaviralci
EP3853229A1 (en) 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
CA3126021A1 (en) * 2019-01-11 2020-07-16 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
JP7514025B2 (ja) * 2019-02-25 2024-07-10 ホーナン メディノ ファーマシューティカル テクノロジー カンパニー リミテッド Ｊａｋ阻害剤化合物及びその使用
MX2021010545A (es) 2019-03-05 2021-11-17 Incyte Corp Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de la disfunción crónica del aloinjerto pulmonar.
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN115244047A (zh) * 2020-03-18 2022-10-25 四川海思科制药有限公司 一种吲唑衍生物及其在医药上的应用
CN111620868B (zh) * 2020-05-28 2021-08-31 爱斯特（成都）生物制药股份有限公司 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法
EP4359402A1 (en) 2021-06-25 2024-05-01 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
CN114181055A (zh) * 2021-12-21 2022-03-15 苏州楚凯药业有限公司 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
WO2011084486A1 (en) 2009-12-21 2011-07-14 Epitherix, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
ME02883B (me) 2013-12-05 2018-04-20 Pfizer PIROLO[2,3-d]PIRIMIDINIL-, PIROLO[2,3-b]PIRAZINIL- I PIROLO[2,3-d] PIRIDINILAKRILAMIDI
CR20160525A (es) 2014-05-14 2016-12-20 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
US10851097B2 (en) 2015-11-03 2020-12-01 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
PT3371185T (pt) 2015-11-03 2020-12-28 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
AU2016350816B2 (en) 2015-11-03 2020-06-25 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
EA037261B1 (ru) 2017-03-09 2021-03-01 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Ингибиторы jak, содержащие 4-членный гетероциклический амид
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CA3059785A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
KR20200003121A (ko) 2017-05-01 2020-01-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물의 결정형

Also Published As

Publication number Publication date
AU2018261593A1 (en) 2019-10-17
US10493077B2 (en) 2019-12-03
JP7098656B2 (ja) 2022-07-11
CY1125051T1 (el) 2024-02-16
US20200046719A1 (en) 2020-02-13
US20220008428A1 (en) 2022-01-13
CN110573508A (zh) 2019-12-13
MD3601283T2 (ro) 2022-05-31
CA3056283A1 (en) 2018-11-08
SG11201908604YA (en) 2019-10-30
SI3601283T1 (sl) 2022-04-29
KR102550225B1 (ko) 2023-07-03
AR111495A1 (es) 2019-07-17
MA47970B1 (fr) 2022-03-31
AU2018261593B2 (en) 2021-08-26
PT3601283T (pt) 2022-02-10
PH12019502264A1 (en) 2020-09-21
EP3601283A1 (en) 2020-02-05
US11160810B2 (en) 2021-11-02
SMT202200079T1 (it) 2022-03-21
PL3601283T3 (pl) 2022-05-02
MX2019012942A (es) 2019-12-16
JP2020518581A (ja) 2020-06-25
DK3601283T3 (da) 2022-04-04
ES2908756T3 (es) 2022-05-03
BR112019022648A2 (pt) 2020-05-19
EP3601283B1 (en) 2021-12-29
HRP20220330T1 (hr) 2022-05-13
NZ757570A (en) 2021-07-30
IL270231A (es) 2019-12-31
WO2018204238A1 (en) 2018-11-08
EA201992601A1 (ru) 2020-03-03
KR20190142389A (ko) 2019-12-26
RS62995B1 (sr) 2022-03-31
CL2019003086A1 (es) 2020-01-24
CN110573508B (zh) 2022-07-05
LT3601283T (lt) 2022-02-25
TW201841914A (zh) 2018-12-01
US20180311255A1 (en) 2018-11-01
IL270231B1 (en) 2023-04-01
TWI760486B (zh) 2022-04-11
IL270231B2 (en) 2023-08-01
UA124478C2 (uk) 2021-09-22
CO2019011809A2 (es) 2020-01-17

Similar Documents

Publication Publication Date Title
MX388751B (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
MX374605B (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria.
MX388750B (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
PH12020500528A1 (en) Pyrimidine compound as jak kinase inhibitor
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
MX2020007265A (es) Derivados de rapamicina.
MX373154B (es) Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
MX2021004582A (es) Compuesto 2-azabiciclo hexano inhibidor de jak.
PH12021550388A1 (en) Process for preparing jak inhibitors and intermediates thereof
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201890752A1 (ru) Способ получения противогрибковых соединений
EA201792021A1 (ru) Ингибитор jak
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
MX2018001699A (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1.
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EA201692300A1 (ru) Производные карбоксамида
EA201790632A1 (ru) 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса
EA201791645A1 (ru) Новые соли и полиморфы scy-078
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
MX389261B (es) Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos.
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam